Showing 15 posts of 214 posts found.


Kirin Holdings to withdraw from 30 year venture with Amgen, sell shares for $780m

October 31, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Kirin, joint venture, pharma

Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would …


Mylan and Biocon Neulasta biosimilar knocked back by FDA

October 11, 2017
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical

Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …


CytomX scores deal with Amgen worth potential $1.5bn

October 4, 2017
Research and Development, Sales and Marketing Amgen, biotech, cytomx, drugs, pharma, pharmaceutical

CytomX Therapeutics and Amgen have signed a deal that could be worth a potential $1.5 billion. The agreement will see …


Five more biosimilar-free years for AbbVie’s megablockbuster

September 28, 2017
Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical

Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …

FDA approves first-ever biosimilar for cancer treatment

September 15, 2017
Medical Communications, Sales and Marketing Amgen, Cancer, FDA, Mvasi, avastin, biosimilar

The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer …


Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%

September 7, 2017
Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab

An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …

FDA refuses approval of Amgen osteoporosis drug

July 17, 2017
Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

Pfizer’s biosimilar gets a second knock-back from FDA

June 23, 2017
Medical Communications, Sales and Marketing Amgen, Epogen, FDA, Pfizer

Pfizer has been dealt a stinging blow by the FDA, after it received a second complete response letter from the …


Breakthrough treatment for ovarian cancer displays promising results

June 5, 2017
Research and Development, Sales and Marketing Amgen, Cancer, ICR, ovarian cancer

A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking …


Amgen hit by major safety blow on osteoporosis drug

May 22, 2017
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB SA

Amgen and UCB SA have been delivered a crushing blow in its attempt to have a drug for osteoporosis approved …


Amgen accuses biosimilar producer of ‘massive conspiracy’

March 9, 2017
Medical Communications Amgen, Coherus, Neulasta, biosimilars

Amgen has filed a lawsuit in a Californian state court against Coherus Biosciences, suggesting that Coherus had stolen trade secrets. …

Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent

February 9, 2017
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent

Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …


Amgen drug pair become first Humira biosimilars to win EU approval

January 30, 2017
Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis

Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …


Amgen and Immatics enter $1bn immuno-oncology partnership

January 9, 2017
Research and Development, Sales and Marketing Amgen, immatics, immunotherapy

Amgen has announced it is to join forces with cancer immunotherapy biotech Immatics Biotechnologies in a partnership potentially worth over …

Latest content